LIGAND PHARMACEUTICALS INCORPORATED Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2022-01: Study NCT04627831; Company role Lead sponsor; Phase Phase 2; Status Withdrawn.
- 2021-01-12: Study NCT04629976; Company role Collaborator; Phase Phase 1; Status Completed.
- 2020-03-18: Study NCT04309526; Company role Collaborator; Phase Phase 1; Status Completed.
- 2019-04-12: Study NCT03869983; Company role Collaborator; Phase Not applicable; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2022-01 | NCT04627831 Comparison of Captisol-Enabled™ Iohexol and Omnipaque™ in Patients With Impaired Renal Function Undergoing Coronary Angiography | Lead sponsor | Phase 2 | Withdrawn | Contrast-induced Nephropathy | 0 | 2023-04 |
| 2021-01-12 | NCT04629976 Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis B | Collaborator Lead: Nucorion Pharmaceuticals, Inc. | Phase 1 | Completed | Chronic Hepatitis B | 21 | 2022-12-28 |
| 2020-03-18 | NCT04309526 Safety, Tolerability and Pharmacokinetics of NCO-48 Fumarate in Healthy Subjects | Collaborator Lead: Nucorion Pharmaceuticals, Inc. | Phase 1 | Completed | Hepatitis B | 48 | 2020-10-13 |
| 2019-04-12 | NCT03869983 Relative Bioavailability of CE-Iohexol (Captisol-enabled™ Iohexol) Injection and Omnipaque™ Injection | Collaborator Lead: CyDex Pharmaceuticals, Inc. | Not applicable | Completed | Contrast-induced Nephropathy; Coronary Angiography | 24 | 2019-06-15 |
| 2016-09 | NCT02851849 A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus | Lead sponsor | Phase 2 | Completed | Type 2 Diabetes Mellitus | 148 | 2017-06 |
| 2016-02 | NCT02672839 A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation | Lead sponsor | Phase 1 | Completed | Type 2 Diabetes Mellitus (T2DM) | 12 | 2016-05 |
| 2014-10 | NCT02250222 Safety and Tolerability Study of Oral LGD-6972 for Type 2 Diabetes Mellitus | Lead sponsor | Phase 1 | Completed | Type 2 Diabetes Mellitus | 48 | 2015-06 |
| 2013-11 | NCT01919684 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus | Lead sponsor | Phase 1 | Completed | Type 2 Diabetes Mellitus | 56 | 2014-03 |
| 2010-06 | NCT01128959 Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy | Collaborator Lead: Lundbeck LLC | Phase 3 | Completed Results posted | Epilepsy | 108 | 2013-01 |
| 2009-04 | NCT00879112 Study of MB07811 in Subjects With Hypercholesterolemia | Lead sponsor | Phase 2 | Withdrawn | Hypercholesterolemia | 80 | 2009-12 |
| 2008-03 | NCT00635232 A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension | Lead sponsor | Phase 2 | Completed Results posted | Hypertension | 261 | 2008-12 |
| 2008-02 | NCT00940953 Compare Captisol-Enabled (CE) Budesonide + Azelastine Nasal Solution and Rhinocort Aqua + Astelin in an Environmental Exposure Chamber (EEC) Study of Allergic Rhinitis | Lead sponsor | Phase 2 | Completed | Seasonal Allergic Rhinitis | 108 | 2008-05 |
| 2008-02 | NCT00626418 The Effects of Aplindore on the Treatment of Signs and Symptoms of Restless Legs Syndrome | Lead sponsor | Phase 2 | Completed | Restless Legs Syndrome | 24 | |
| 2008-01 | NCT00623324 The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's Disease | Lead sponsor | Phase 2 | Completed | Early Stage Parkinson's Disease | 40 | |
| 2007-08 | NCT00522925 A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension | Lead sponsor | Phase 2 | Completed Results posted | Hypertension | 280 | 2008-05 |
| 2007-03 | NCT00458016 Safety, Tolerability, and Efficacy Study of MB07803 Administered to Patients With Type 2 Diabetes Mellitus | Lead sponsor | Phase 2 | Completed | Type 2 Diabetes Mellitus | 105 | 2008-03 |
| 2007-02 | NCT00938613 Compare CE-Budesonide Nasal Solution & Rhinocort Aqua in an EEC Study of AR | Lead sponsor | Phase 2 | Completed | Seasonal Allergic Rhinitis | 65 | 2007-04 |
| 2005-12 | NCT00125372 Study of Tarceva and Targretin in Stage I-II Lung Cancer | Collaborator Lead: Dartmouth-Hitchcock Medical Center | Not applicable | Completed Results posted | Carcinoma, Non-small-cell Lung | 12 | 2010-08 |
| 2005-08 | NCT00125359 Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer | Collaborator Lead: Konstantin Dragnev | Phase 2 | Completed Results posted | Carcinoma, Non-small-cell Lung | 42 | 2014-03 |
| 2004-09 | NCT00674453 The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation | Lead sponsor | Phase 2 | Completed | Bone Loss | 51 | 2007-09 |
| 2004-06 | NCT00143273 Dose Response Study of Lasofoxifene in Postmenopausal Women With Osteoporosis - Japanese Asian Dose Evaluation | Lead sponsor | Phase 2 | Completed | Osteoporosis | 497 | 2006-03 |
| 2004-04 | NCT00238628 A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer | Collaborator Lead: Stanford University | Phase 1, Phase 2 | Completed | Lung Cancer | 6 | 2005-12 |
| 2003-11 | NCT00151008 Bexarotene With Narrow-Band UVB for Psoriasis | Collaborator Lead: University of Medicine and Dentistry of New Jersey | Phase 2 | Completed | Psoriasis | 35 | 2005-08 |
| 2003-09 | NCT00073736 Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma | Lead sponsor | Phase 1, Phase 2 | Completed | Hepatocellular Carcinoma | 28 | |
| 2003-05 | NCT00163137 Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss | Lead sponsor | Phase 3 | Completed | Osteoporosis | 540 | 2005-10 |
| 2003-05 | NCT00063076 Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata | Collaborator Lead: M.D. Anderson Cancer Center | Phase 2, Phase 3 | Completed | Alopecia Areata | 46 | 2007-05 |
| 2003-04 | NCT01116622 Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancers of the Aerodigestive Tract | Collaborator Lead: Dartmouth-Hitchcock Medical Center | Phase 1 | Completed | Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus) | 24 | 2014-04 |
| 2001-12 | NCT00306969 Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma | Collaborator Lead: Boston University | Phase 1, Phase 2 | Completed | Cutaneous T-Cell Lymphoma | 18 | 2004-04 |
| 2001-11 | NCT00141323 Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL) | Lead sponsor | Phase 3 | Completed | Osteoporosis | 8,556 | 2007-12 |
| 2001-08 | NCT00153842 A Study of Paclitaxel and Carboplatin in Combination With Bexarotene Oral Capsules in Patients With Advanced Lung Cancer | Collaborator Lead: Dartmouth-Hitchcock Medical Center | Phase 1, Phase 2 | Terminated Results posted | Carcinoma, Non-small-cell Lung | 33 | 2009-03 |
| 2001-05 | NCT00211198 Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) | Collaborator Lead: Eisai Inc. | Phase 4 | Completed | Lymphoma, T-Cell, Cutaneous | 60 | 2006-01 |
| 2001-04 | NCT00322296 Phase II Trial to Evaluate the Efficacy of Topical Bexarotene Gel in Patients With Parapsoriasis | Collaborator Lead: Fox Chase Cancer Center | Phase 2 | Terminated | Parapsoriasis | 8 | 2004-08 |
| 1999-11 | NCT00006345 Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma | Lead sponsor | Phase 2 | Completed | Drug/Agent Toxicity by Tissue/Organ; Lymphoma | 2004-03 | |
| 1998-10 | NCT00003752 Bexarotene in Treating Patients With Metastatic Breast Cancer | Lead sponsor | Phase 2 | Completed | Breast Cancer | 180 | 2003-03 |
| NCT00002439 A Study of ALRT 1057 Topical Gel in Patients With AIDS-Related Kaposi's Sarcoma | Collaborator Lead: Anderson Clinical Research | Not applicable | Completed | Sarcoma, Kaposi; HIV Infections | |||
| NCT00002212 A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma | Lead sponsor | Phase 2 | Completed | Sarcoma, Kaposi; HIV Infections | 27 | ||
| NCT00002188 A Study of ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma | Collaborator Lead: Anderson Clinical Research | Phase 2 | Completed | Sarcoma, Kaposi; HIV Infections | 27 |